389 related articles for article (PubMed ID: 22023537)
1. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
Morishita Y; Kusano E
Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
[TBL] [Abstract][Full Text] [Related]
2. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
3. The effects of direct renin inhibitor, aliskiren, on arterial hypertension, chronic kidney disease and cardiovascular disease: optimal pharmacotherapy.
Morishita Y; Kusano E
Cardiovasc Hematol Agents Med Chem; 2013 Mar; 11(1):77-82. PubMed ID: 22827288
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
5. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
6. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
7. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
Hershon KS
Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
10. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.
Tsukamoto O; Kitakaze M
Cardiovasc Drugs Ther; 2013 Apr; 27(2):133-8. PubMed ID: 22147138
[TBL] [Abstract][Full Text] [Related]
11. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients.
Aftab RA; Khan AH; Adnan AS; Jannah N
Ren Fail; 2016; 38(3):474-80. PubMed ID: 26853680
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
Gullapalli N; Bloch MJ; Basile J
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
[TBL] [Abstract][Full Text] [Related]
14. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
Rastogi A; Rashid M; Wright RF
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
[TBL] [Abstract][Full Text] [Related]
15. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
Pende A; Montecucco F
Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
[No Abstract] [Full Text] [Related]
17. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
Volpe M; Santolamazza C; Tocci G
Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
[TBL] [Abstract][Full Text] [Related]
18. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
Nussberger J; Bohlender J
Nat Rev Cardiol; 2013 Apr; 10(4):183-4. PubMed ID: 23478259
[TBL] [Abstract][Full Text] [Related]
20. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
Ferrari R; Boersma E
Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
